Computational identification of microRNAs associated to both epithelial to mesenchymal transition and NGAL/MMP-9 pathways in bladder cancer

Oncotarget

Volumn 7, Issue 45, 2016, Pages 72758-72766

  Falzone, Luca ^a   Candido, Saverio ^a   Salemi, Rossella ^a   Basile, Maria S ^a   Scalisi, Aurora ^b   McCubrey, James A ^c   Torino, Francesco ^d   Signorelli, Salvatore S ^e   Montella, Maurizio ^f   Libra, Massimo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b Secondary Prevention and Screening Gynecological Unit   (Italy)

^c EAST CAROLINA UNIVERSITY   (United States)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e UNIVERSITY OF CATANIA   (Italy)

^f NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Bioinformatics; Bladder cancer; Epithelial mesenchymal transition; MiRNAs; NGAL MMP 9

Indexed keywords

GELATINASE B; HSA MICRORNA 106B 5P; HSA MICRORNA 125B 5P; HSA MICRORNA 143 3P; HSA MICRORNA 145 5P; HSA MICRORNA 17 5P; HSA MICRORNA 182 5P; HSA MICRORNA 18B 5P; HSA MICRORNA 19B 3P; HSA MICRORNA 200A 3P; HSA MICRORNA 200A 5P; HSA MICRORNA 200B 5P; HSA MICRORNA 20A 5P; HSA MICRORNA 214 3P; HSA MICRORNA 425 5P; HSA MICRORNA 99A 5P; MICRORNA; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; UNCLASSIFIED DRUG; UNTRANSLATED RNA; LCN2 PROTEIN, HUMAN;

ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER STAGING; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; HUMAN CELL; RNA ANALYSIS; SOFTWARE; UPREGULATION; BIOLOGY; BLADDER TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUCLEIC ACID DATABASE; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION;

COMPUTATIONAL BIOLOGY; DATABASES, NUCLEIC ACID; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIPOCALIN-2; MATRIX METALLOPROTEINASE 9; MICRORNAS; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

EID: 84995772546     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.11805     Document Type: Article

References (45)

1. Mahdavifar N, Ghoncheh M, Pakzad R, Momenimovahed Z, Salehiniya H. Epidemiology, Incidence and Mortality of Bladder Cancer and their Relationship with the Development Index in the World. Asian Pac J Cancer Prev 2016; 17:381-6.
2. Malats N, Real FX. Epidemiology of Bladder Cancer. Hematology/oncology clinics of North America 2015; 29:177-89.
3. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on day/month/year.
4. Lee HW, Wang HT, Weng MW, Hu Y, Chen WS, Chou D, Liu Y, Donin N, Huang WC, Lepor H, Wu XR, Wang H, Beland FA, et al. Acrolein-and 4-Aminobiphenyl-DNA adducts in human bladder mucosa and tumor tissue and their mutagenicity in human urothelial cells. Oncotarget 2014; 5:3526-40. doi:10.18632/oncotarget.1954.
5. Brait M, Munari E, LeBron C, Noordhuis MG, Begum S, Michailidi C, Gonzalez-Roibon N, Maldonado L, Sen T, Guerrero-Preston R, Cope L, Parrella P, Fazio VM, et al. Genome-wide methylation profiling and the PI3K-AKT pathway analysis associated with smoking in urothelial cell carcinoma. Cell Cycle. 2013; 12:1058-70.
6. Xu X, Zhou L, Miao R, Chen W, Zhou Y, Pang Q, Qu K, Liu C. Association of cancer mortality with postdiagnosis overweight and obesity using body mass index. Oncotarget 2016; 7:5023-9. doi:10.18632/oncotarget.6517.
7. Cantiello F, Cicione A, Salonia A, Autorino R, De Nunzio C, Briganti A, Gandaglia G, Dell'Oglio P, Capogrosso P, Damiano R. Association between metabolic syndrome, obesity, diabetes mellitus and oncological outcomes of bladder cancer: A systematic review. Int J Urol 2015; 22:22-32
8. Goossens ME, Zeegers MP, Bazelier MT, De Bruin ML, Buntinx F, de Vries F. Risk of bladder cancer in patients with diabetes: a retrospective cohort study. BMJ Open 2015; 5:e007470
9. Montella M, Di Maso M, Crispo A, Grimaldi M, Bosetti C, Turati F, Giudice A, Libra M, Serraino D, La Vecchia C, Tambaro R, Cavalcanti E, Ciliberto G, et al. Metabolic syndrome and the risk of urothelial carcinoma of the bladder: a case-control study. BMC Cancer 2015; 15:720.
10. Turati F, Bosetti C, Polesel J, Zucchetto A, Serraino D, Montella M, Libra M, Galfano A, La Vecchia C, Tavani A. Coffee, Tea, Cola, and Bladder Cancer Risk: Dose and Time Relationships. Urology 2015; 86:1179-84.
11. Soubra A, Risk MC. Diagnostics techniques in nonmuscle invasive bladder cancer. Indian J Urol 2015; 31:283-8.
12. Mossanen M, Gore JL. The burden of bladder cancer care: direct and indirect costs. Curr Opin Urol 2014; 24:487-91.
13. James AC, Gore JL. The costs of non-muscle invasive bladder cancer. Urol Clin North Am 2013; 40:261-9.
14. Hafsi S, Candido S, Maestro R, Falzone L, Soua Z, Bonavida B, Spandidos DA, Libra M. Correlation between the overexpression of Yin Yang 1 and the expression levels of miRNAs in Burkitt's lymphoma: A computational study. Oncol Lett 2016; 11:1021-1025.
15. Leonardi GC, Candido S, Carbone M, Colaianni V, Garozzo SF, Cinà D, Libra M. microRNAs and thyroid cancer: biological and clinical significance (Review). Int J Mol Med. 2012; 30:991-9.
16. Braicu C, Cojocneanu-Petric R, Chira S, Truta A, Floares A, Petrut B, Achimas-Cadariu P, Berindan-Neagoe I. Clinical and pathological implications of miRNA in bladder cancer. Int J Nanomedicine 2015; 10:791-800.
17. Martínez-Fernández M, Dueñas M, Feber A, Segovia C, García-Escudero R, Rubio C, López-Calderón FF, Díaz-García C, Villacampa F, Duarte J, et al. A Polycombmir200 loop regulates clinical outcome in bladder cancer. Oncotarget 2015; 6:42258-75. doi:10.18632/oncotarget.5546.
18. Ouyang H, Zhou Y, Zhang L, Shen G. Diagnostic Value of MicroRNAs for Urologic Cancers: A Systematic Review and Meta-Analysis. Medicine (Baltimore) 2015; 94:e1272.
19. Bagnoli M, De Cecco L, Granata A, Nicoletti R, Marchesi E, Alberti P, Valeri B, Libra M, Barbareschi M, Raspagliesi F, Mezzanzanica D, Canevari S. Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients. Oncotarget. 2015; 6:9643. doi:10.18632/oncotarget.3998.
20. Candido S, Di Maso M, Serraino D, McCubrey JA, Bortolus R, Zanin M, Battiston M, Salemi R, Libra M, Polesel J. Diagnostic value of neutrophil gelatinaseassociated lipocalin/matrix metalloproteinase-9 pathway in transitional cell carcinoma of the bladder. Tumour Biol 2016. [Epub ahead of print]
21. Candido S, Abrams SL, Steelman LS, Lertpiriyapong K, Fitzgerald TL, Martelli AM, Cocco L, Montalto G, Cervello M, Polesel J, Libra M, McCubrey JA. Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapy. Biochim Biophys Acta 2016; 1863:438-48.
22. Ricci S, Bruzzese D, DI Carlo A. Evaluation of MMP-2, MMP-9, TIMP-1, TIMP-2, NGAL and MMP-9/NGAL complex in urine and sera from patients with bladder cancer. Oncol Lett 2015; 10:2527-2532.
23. Kim M, Chen X, Chin LJ, Paranjape T, Speed WC, Kidd KK, Zhao H, Weidhaas JB, Slack FJ. Extensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases. Cell Cycle. 2014; 13:1030-40.
24. Anastasiadis A, de Reijke TM. Best practice in the treatment of nonmuscle invasive bladder cancer. Ther Adv Urol 2012; 4:13-32.
25. Aoki S, Yamada Y, Nakamura K, Taki T, Tobiume M, Honda N. Thymidine phosphorylase expression as a prognostic marker for predicting recurrence in primary superficial bladder cancer. Oncol Rep 2006; 16:279-84.
26. Candido S, Maestro R, Polesel J, Catania A, Maira F, Signorelli SS, McCubrey JA, Libra M. Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer. Oncotarget 2014; 5:1576-94. doi:10.18632/oncotarget.1738.
27. Zaravinos A. The Regulatory Role of MicroRNAs in EMT and Cancer. J Oncol. 2015; 2015:865816. Review.
28. Chan SH, Wang LH. Regulation of cancer metastasis by microRNAs. J Biomed Sci. 2015 Jan 23; 22:9. Review.
29. Zhang P, Sun Y, Ma L. ZEB1: at the crossroads of epithelialmesenchymal transition, metastasis and therapy resistance. Cell Cycle. 2015; 14:481-7.
30. Bonavida B, Jazirehi A, Vega MI, Huerta-Yepez S, Baritaki S. Roles Each of Snail, Yin Yang 1 and RKIP in the Regulation of Tumor Cells Chemo-immuno-resistance to Apoptosis. For Immunopathol Dis Therap. 2013; 4.
31. Jiang G, Wu AD, Huang C, Gu J, Zhang L, Huang H, Liao X, Li J, Zhang D, Zeng X, Jin H, Huang H, Huang C. Isorhapontigenin (ISO) Inhibits Invasive Bladder Cancer Formation In Vivo and Human Bladder Cancer Invasion In Vitro by Targeting STAT1/FOXO1 Axis. Cancer Prev Res (Phila). 2016; 9:567-80.
32. Zhang X, Zhang Y. Bladder Cancer and Genetic Mutations. Cell Biochem Biophys. 2015; 73:65-9.
33. Ai X, Jia ZM, Wang J, DI GP, Zhang XU, Sun F, Zang T, Liao X. Bioinformatics analysis of the target gene of fibroblast growth factor receptor 3 in bladder cancer and associated molecular mechanisms. Oncol Lett. 2015; 10:543-549.
34. Zhao Y, Qi JG, Yang N, Lin YL, Liang J, Zhu X. Association between MYC rs9642880[T] allele and bladder cancer risk: a meta-analysis. Genet Mol Res. 2015; 14:14745-51.
35. Duperret EK, Oh SJ, McNeal A, Prouty SM, Ridky TW. Activating FGFR3 mutations cause mild hyperplasia in human skin, but are insufficient to drive benign or malignant skin tumors. Cell Cycle. 2014; 13:1551-9.
36. Sapre N, Macintyre G, Clarkson M, Naeem H, Cmero M, Kowalczyk A, Anderson PD, Costello AJ, Corcoran NM, Hovens CM. A urinary microRNA signature can predict the presence of bladder urothelial carcinoma in patients undergoing surveillance. Br J Cancer 2016; 114:454-62.
37. Ding M, Li Y, Wang H, Lv Y, Liang J, Wang J, Li C. Diagnostic value of urinary microRNAs as non-invasive biomarkers for bladder cancer: a meta-analysis. Int J Clin Exp Med 2015; 8:15432-40.
38. Mirzaei H, Gholamin S, Shahidsales S, Sahebkar A, Jaafari MR, Mirzaei HR, Hassanian SM, Avan A. MicroRNAs as potential diagnostic and prognostic biomarkers in melanoma. Eur J Cancer 2016; 53:25-32.
39. Chang PY, Chen CC, Chang YS, Tsai WS, You JF, Lin GP, Chen TW, Chen JS, Chan EC. MicroRNA-223 and microRNA-92a in stool and plasma samples act as complementary biomarkers to increase colorectal cancer detection. Oncotarget. 2016; 7:10663-75. doi:10.18632/oncotarget.7119.
40. Brunetti O, Russo A, Scarpa A, Santini D, Reni M, Bittoni A, Azzariti A, Aprile G, Delcuratolo S, Signorile M, Gnoni A, Palermo L, Lorusso V, et al. MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets? Oncotarget. 2015; 6:23323-41. doi:10.18632/oncotarget.4492.
41. Frères P, Wenric S, Boukerroucha M, Fasquelle C, Thiry J, Bovy N, Struman I, Geurts P, Collignon J, Schroeder H, Kridelka F, Lifrange E, Jossa V, et al. Circulating microRNA-based screening tool for breast cancer. Oncotarget. 2016; 7:5416-28. doi:10.18632/oncotarget.6786.
42. Xu C, Zeng Q, Xu W, Jiao L, Chen Y, Zhang Z, Wu C, Jin T, Pan A, Wei R, Yang B, Sun Y. miRNA-100 inhibits human bladder urothelial carcinogenesis by directly targeting mTOR. Mol Cancer Ther 2013; 12:207-19.
43. Hecker N, Stephan C, Mollenkopf HJ, Jung K, Preissner R, Meyer HA. A new algorithm for integrated analysis of miRNA-mRNA interactions based on individual classification reveals insights into bladder cancer. PLoS One 2013; 8:e64543.
44. Shirdel EA, Xie W, Mak TW, Jurisica I. NAViGaTing the Micronome. Using Multiple MicroRNA Prediction Databases to Identify Signalling Pathway-Associated MicroRNAs. PLoS ONE 2011; 6:e17429.
45. Polesel J, Franceschi S, Talamini R, Negri E, Barzan L, Montella M, Libra M, Vaccher E, Franchin G, La Vecchia C, Serraino D. Tobacco smoking, alcohol drinking, and the risk of different histological types of nasopharyngeal cancer in a low-risk population. Oral Oncol. 2011; 47:541-5.